This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Identification of Molecular Biomarkers to Stratify Patients With Refractory Asthma

This study has been completed.
MedImmune LLC
Information provided by (Responsible Party):
National Jewish Health Identifier:
First received: April 27, 2012
Last updated: March 27, 2017
Last verified: March 2017
The purpose of this study is to learn more about asthma in people who are not well-controlled with current asthma medication (refractory asthma). The investigators will compare data from refractory asthmatic patients here at National Jewish Health to mild asthmatics subjects and to people without asthma. Study experiments involve looking at samples from all 3 groups and comparing them at a molecular level. These laboratory experiments may help identify subtypes of refractory asthmatics that require different treatments.


Study Type: Observational
Study Design: Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Identification of Molecular Biomarkers to Stratify Patients With Refractory Asthma

Further study details as provided by National Jewish Health:

Primary Outcome Measures:
  • Determining phenotypes non-invasively [ Time Frame: October, 2015 ]
    Comparing invasive phenotyping to non-invasive

Biospecimen Retention:   Samples Without DNA
Blood and lung samples will be retained for RNA purposes.

Enrollment: 110
Study Start Date: January 2012
Study Completion Date: June 2016
Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
We are looking for mild non-smoking asthmatic adults who are well-controlled with their asthma therapy (non-refractory asthmatics).

Inclusion Criteria:

  • Able to receive Informed Consent
  • At least 18 years of age
  • ICS < 880 mcg (FP equivalents)
  • PC20<=16 mg/mL
  • No more than 1 oral steroid bursts in previous 12 months
  • Less that 3 urgent care visit in previous 12 months
  • No deterioration with <=25% decrease in steroids
  • No near fatal asthma event

Exclusion Criteria:

  • Pregnancy
  • Current smoker, smoking within the past year or pack/year history >10 years
  • Respiratory infection within past 6 weeks
  • Antibiotics within the past 6 weeks
  • Active lung disease other than asthma
  • Cancer within past 5 years (excluding basal cell skin cancer)
  • Active or chronic infection
  • Hematological or autoimmune disease
  • Unable to safely undergo bronchoscopy as determined by doctor or study doctor
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01589198

United States, Colorado
National Jewish Health
Denver, Colorado, United States, 80121
Sponsors and Collaborators
National Jewish Health
MedImmune LLC
Principal Investigator: Richard Martin, MD National Jewish Health
  More Information

Responsible Party: National Jewish Health Identifier: NCT01589198     History of Changes
Other Study ID Numbers: NJH HS-2639
Study First Received: April 27, 2012
Last Updated: March 27, 2017

Keywords provided by National Jewish Health:

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases processed this record on September 21, 2017